Find therapies in clinical trials near you – page 3

Study Comparing Acalabrutinib and Venetoclax with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study Comparing Acalabrutinib and Venetoclax with Venetoclax and Obinutuzumab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study on Acalabrutinib for Very Old or Frail Patients with Chronic Lymphocytic Leukemia

Study on Acalabrutinib for Very Old or Frail Patients with Chronic Lymphocytic Leukemia

Study Comparing ACP-196 and Ibrutinib for Patients with High-Risk Chronic Lymphocytic Leukemia

Study Comparing ACP-196 and Ibrutinib for Patients with High-Risk Chronic Lymphocytic Leukemia

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Study on the Effects of Acalabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Study on Acalabrutinib and Venetoclax for Newly Diagnosed Chronic Lymphocytic Leukemia Patients at High Risk of Infection and Early Treatment Needs

Study on Acalabrutinib and Venetoclax for Newly Diagnosed Chronic Lymphocytic Leukemia Patients at High Risk of Infection and Early Treatment Needs

Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Study of Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Study of Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Study of Acalabrutinib, Venetoclax, and Rituximab for Patients with Newly Diagnosed Mantle Cell Lymphoma

Study of Acalabrutinib, Venetoclax, and Rituximab for Patients with Newly Diagnosed Mantle Cell Lymphoma

Study of Acalabrutinib Alone or with Rituximab for Patients with Relapsed/Refractory Marginal Zone Lymphoma

Study of Acalabrutinib Alone or with Rituximab for Patients with Relapsed/Refractory Marginal Zone Lymphoma